green tea extract
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02891538 | Jan 2017 → Jun 2024 | colon carcinoma | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01239095 | Jul 2011 → Feb 2023 | colon carcinoma | Richard Whelan | Terminated | No outcome recorded |
| Phase 1 | NCT00302289 | Jan → Dec 2000 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06615752 | Oct 2026 → Apr 2028 expected | prostate carcinoma | Charles Drew University of Medicine and Science | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06875791 | Dec 2025 → Dec 2026 expected | head and neck squamous cell carcinoma, mucositis | Fundacion Clinica Valle del Lili | Not yet recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT04898023 | Sep 2022 → Oct 2023 | viral respiratory tract infection | University of Missouri-Columbia | Terminated | No outcome recorded |
| Phase 2 | NCT04300855 | Aug 2020 → Feb 2027 expected | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03622762 | Jul 2018 → Mar 2019 | diabetic kidney disease | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 2 | NCT02627898 | Jan → Sep 2016 | type 2 diabetes mellitus | Centro Universitario de Ciencias de la Salud, Mexico | Completed | No outcome recorded |
| Phase 2 | NCT01928485 | Aug 2013 → Oct 2016 | prostate carcinoma | Sanjay Gupta PhD | Terminated | No outcome recorded |
| Phase 2 | NCT00917735 | Jul 2009 → Jun 2014 | breast cancer | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00844792 | Oct 2008 → Dec 2013 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT00744549 | May 2008 → Dec 2013 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT00918060 | Feb 2008 → Dec 2010 | periodontitis | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT00176566 | Sep 2003 → Nov 2006 | oral mucosa leukoplakia | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00302263 | Jan → Apr 2005 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 2/3 | NCT00302276 | Jan → Jul 2004 | obesity disorder | University of Copenhagen | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05364008 | Jan 2023 → Jun 2026 overdue | leiomyoma | Yale University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02329600 | Jun 2013 → Aug 2014 | lichen planus, oral | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT00383058 | Sep 2006 → Jun 2007 | obesity disorder | Taipei City Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05803590 | May → Jul 2023 | gingivitis | Cairo University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03415165 Comparator | Jan 2018 → Jan 2019 | lichen planus, oral | Cairo University | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Green Tea Extract | “The objective of the present study was to investigate the acute and sub-chronic effect of a supplement containing green tea extract, capsaisin, caffeine, tyrosine and calcium...” NCT00302276 ↗15“Where patients in this group will receive a buccal tablet containing 200 mg of green tea extract which adheres to the buccal mucosa slowly releasing the polyphenoles along...” NCT03415165 ↗ “All treatments were administered as tablets containing either 500 mg green tea extract (whereof 125 mg cate-chins), 400 mg tyrosine, 50 mg anhydrous caffeine, or placebo.” NCT00302289 ↗ “In this study, we aimed to evaluate the effect of locally delivered gel containing green tea extract as an adjunct to non-surgical periodontal treatment.” PMID 25523604 ↗ Dec 2014 “AIMS: To examine the effect of green tea extract (GTE) on obese women and to explore the relationship between GTE and obesity-related hormone peptides.” PMID 18468736 ↗ May 2008 “Bioactive Metobes compound (green tea extract, tyrosine, caffeine and capsaicin) without calcium together with 5 mg propranolol.” NCT00302263 ↗ “Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU” NCT00844792 ↗ “Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day” NCT01239095 ↗ “Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E” NCT00744549 ↗ |
| Known as | Camella sinensis gel | “Drug: Camella sinensis gel” NCT00918060 ↗ |
| Known as | Epigallocatechin gallate (EGCG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02891538 ↗ |
| Known as | Green tea | “The purpose of this study is to determine whether taking a green tea preparation may have effects on your leukoplakia.” NCT00176566 ↗ |
| Known as | Green Tea Catechin | “This randomized double-blinded Phase II clinical trial will evaluate the bioavailability, safety, effectiveness and validate the mechanism by which a standardized formulation...” NCT04300855 ↗ |
| Known as | Green Tea Extract: EGCg | “Green Tea Extract: EGCg” NCT01239095 ↗ |
| Known as | GTE | “AIMS: To examine the effect of green tea extract (GTE) on obese women and to explore the relationship between GTE and obesity-related hormone peptides.” PMID 18468736 ↗ May 20082“It has known that green tea extract (GTE) increases the expression of sRAGE, but it is unknown whether this could improve kidney function.” PMID 34788550 ↗ Nov 2021 “Green tea extract (GTE) is a potential mitigator of oxidative stress, and F2-isoprostanes are a reliable biomarker of oxidative stress.” PMID 37011435 ↗ Mar 2023 |
| Known as | Sunphenon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01928485 ↗ |
| Route | Oral | “Women in the GTE group orally took 4 decaffeinated capsules containing 1315 mg total catechins including 843 mg epigallocatechin-3-gallate daily for 1 y” PMID 30926986 ↗ Apr 2019 |